Lifevantage Corp. 10-Q Summary: Period Ended December 31, 2010
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2010, and the six-month period ended on that date. Lifevantage Corporation is a dietary supplement company primarily marketing Protandim and LifeVantage TrueScience Anti-Aging Cream through network marketing and direct-to-consumer channels. The company operates in the U.S., Japan, and Mexico, with substantially all long-lived assets located in the U.S.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2010 | Six Months Ended Dec 31, 2010 |
|---|---|---|
| Net Revenue | $7,460,089 | $13,903,438 |
| Gross Profit | $6,268,555 (84% margin) | $11,691,769 (84% margin) |
| Operating Income | $608,982 | $953,751 |
| Net Income | $5,447,624 | $6,162,817 |
| Cash and Equivalents | $2,736,172 (as of Dec 31, 2010) | |
| Working Capital | $(818,406) (Negative) | |
| Total Liabilities | $12,009,837 | |
| Convertible Debt (Net) | $107,826 (Short-term: $29,445; Long-term: $78,381) | |
| Derivative Liabilities | $8,062,740 (Short-term: $1,716,141; Long-term: $6,346,599) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased significantly compared to the prior year periods. For the six months ended Dec 31, 2010, revenue was $13.9 million versus $4.3 million in the same period in 2009. This growth is attributed to increased sales volume through the network marketing channel, with Japan operations contributing $2.8 million in the six-month period.
- Profitability: The company reported a net income of $6.2 million for the six months ended Dec 31, 2010, compared to $2.2 million in the prior year period. This improvement is largely driven by a non-cash gain of $7.3 million from the change in fair value of derivative liabilities.
- Operating Expenses: Sales and marketing expenses increased to $7.4 million (six months) from $4.0 million (prior year) due to higher distributor commissions and sales events. Conversely, General and Administrative expenses decreased to $3.0 million from $4.9 million due to reduced legal and personnel costs.
- Balance Sheet: Total liabilities decreased from $22.4 million (June 30, 2010) to $12.0 million (Dec 31, 2010), primarily due to a reduction in derivative liabilities and the conversion of debt to equity.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: Net income is heavily influenced by the change in fair value of derivative liabilities, which generated $7.3 million in income for the six-month period. This is a non-cash item resulting from the valuation of embedded conversion options and warrants on convertible debt.
- Liquidity: The company reported negative working capital of $(818,406), primarily due to the classification of certain derivative liabilities as short-term. However, management believes existing cash and future cash flows are sufficient for operations for at least the next 12 months.
- Risks: Key risks include significant dependence on a single product (Protandim), the potential failure of the network marketing sales channel, and the volatility of derivative liability valuations. The company also faces risks related to government regulation of the dietary supplement industry and potential product liability claims.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding inadequate oversight of accounting functions and a lack of formal policies. Remediation is planned by June 30, 2011.
- Outlook: The company expects to continue investing in research and development (approximately 2% of net revenue) and anticipates continued increases in sales and marketing expenses as sales grow.
Investor Verification Checklist
- Verify the sustainability of revenue growth independent of the non-cash gains from derivative liability revaluations.
- Assess the impact of the negative working capital position and the classification of derivative liabilities on short-term liquidity.
- Review the status of remediation efforts for the identified material weaknesses in internal controls over financial reporting.
- Monitor the concentration risk associated with reliance on the single product, Protandim, and the network marketing distribution model.
- Confirm the valuation assumptions used for derivative liabilities, as these significantly impact reported net income.